Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519233 · ClinicalTrials.gov registry record · Phase 1
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00519233 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 13 participants.
The verdict
NCT00519233, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of AGS-1C4D4 in patients with advanced HRPC.
Interventions
- DRUG AGS-1C4D4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00519233
The ClinicalTrials.gov registry entry for NCT00519233 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AGS-1C4D4 is the first listed.
NCT00519233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00519233 about?
NCT00519233 is a clinical study titled "AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer". The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of AGS-1C4D4 in patients with advanced HRPC.
What is the current status of trial NCT00519233?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2007-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00519233?
The interventions under investigation include: AGS-1C4D4 (DRUG).
Who is sponsoring clinical trial NCT00519233?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.